Nomura Asset Management Co. Ltd. Has $11.63 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Nomura Asset Management Co. Ltd. decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 97.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 149,476 shares of the medical device company’s stock after selling 6,004,705 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in DexCom were worth $11,625,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of DXCM. Norges Bank purchased a new position in shares of DexCom in the fourth quarter worth approximately $385,367,000. Congress Asset Management Co. boosted its stake in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD purchased a new position in DexCom during the 4th quarter worth approximately $96,507,000. Two Sigma Advisers LP raised its stake in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after purchasing an additional 739,000 shares during the period. Finally, Jennison Associates LLC lifted its holdings in shares of DexCom by 10.3% in the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 32,498 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 105,009 shares of company stock worth $8,044,178. Company insiders own 0.30% of the company’s stock.

DexCom Trading Down 2.5 %

Shares of DXCM stock opened at $67.74 on Monday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $141.99. The company has a market cap of $26.47 billion, a PE ratio of 47.37, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $82.32 and its two-hundred day moving average is $77.13.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on DXCM shares. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.